CD34 and neoplasm: We developed and optimized this procedure for immunocapture of CD34+ blast-derived exosomes from AML plasma in expectation that it will provide a specific tool for separation of tumor-derived immunologically-active exosomes from the bulk of those present in plasma and for discrimination of their potentially different biologic activities.